The optimum imaging modality for the screening of multiple endocrine neoplasia type 1 (MEN1)-associated tumors is not well established. Here, we compare the performance of contrast-enhanced CT (CECT) versus
68
Ga DOTA-NOC/TATE PET/CT in MEN1 patients. The retrospective case record study is conducted at a tertiary health-care center. Thirty-four patients, who have undergone both CECT and
68
Ga DOTA-NOC/ TATE PET, were included in the analysis. CECT had higher per-lesion sensitivity than
68
Ga DOTA-NOC/TATE PET/CT for the detection of parathyroid lesions, (82.6% vs. 24.6%,
P
< 0.001).
68
Ga DOTA-NOC/TATE PET/CT had higher per-lesion sensitivity than CECT for the detection of metastases (85% vs. 47.5%,
P
< 0.001) and gastrinomas (90% vs. 10%,
P
= 0.003). When combined use of the two imaging modalities is compared to CECT alone (63.7% vs. 93.1%,
P
= 0.00012) and
68
Ga-DOTA-NOC/TATE PET/CT alone (74.1% vs. 93.1%,
P
= 0.0057), it provided significantly higher per-lesion sensitivity for the detection of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
68
Ga-DOTA-NOC/ TATE PET was more sensitive for the detection of gastrinomas and metastases than CECT, whereas it was less sensitive for the detection of parathyroid lesions than CECT. The combined use of both the imaging modalities significantly increases the sensitivity for detection of GEP-NETs.